ArticleNature communications2025
Ameba-inspired strategy enhances probiotic efficacy via prebound nutrient supply.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A barrier-centered perspective on the gut-barrier-bone axis: a review of the core role of the intestinal barrier and related probiotics with nanocoatings.Archives of microbiology · 2026Review
- Oral probiotic delivery-based therapeutic strategies for inflammatory bowel disease.Asian journal of pharmaceutical sciences · 2026Review
- Crafting probiotics a self-polymerized smart outfit for effective ulcerative colitis treatment.Journal of nanobiotechnology · 2026Article
- Modular design for drug delivery across hierarchical gastrointestinal barriers: From materials to systems.Materials today. Bio · 2026Review
- Prodrug-integrated multifunctional liposome encapsulation enhances probiotic-based bacteriotherapy for inflammatory bowel disease.Materials today. Bio · 2026Article
- A multifunctional probiotic co-delivery platform for the treatment of Clostridium difficile infection.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Harnessing a germ‑free mouse gut bioreactor for directed evolution of probiotics to combat non-alcoholic fatty liver disease.Nature communications · 2026Article
- Untargeted Metabolomics Reveals Raw Material Geographic Origin as a Key Factor Shaping the Quality of Ginger-Derived Exosome-like Nanovesicles.Foods (Basel, Switzerland) · 2026Article
- The challenges and strategies for navigatingTheranostics · 2026Review
- Oral Delivery of R-spondin1-Loaded Small Extracellular Vesicles Activates WNT Signalling Pathway to Accelerate Intestinal Injury Repair and Reverse Ageing.Journal of extracellular vesicles · 2026Article
- Application of stem cell-derived exosomes in skin wound healing: mechanisms, prospects, and challenges.Frontiers in immunology · 2026Review
- Probiotic living microneedles designed by interbacterial competition for accelerated infected wound healing.Acta pharmaceutica Sinica. B · 2025Article
- Surface modification of probiotics at single-cell resolution: Strategies, applications, and future directions in inflammatory bowel disease.Materials today. Bio · 2025Review
- Cross-platform assessment of short-form video quality on the gut-liver axis: informational integrity and engagement disparity.Frontiers in cellular and infection microbiology · 2025Article
- Traditional Chinese medicine derived exosome-like nanovesicles in wound repair and skin regeneration.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nutrient competition with indigenous microbes or pathogens presents a significant challenge for oral probiotic efficacy. To address this issue, we develop an ameba-inspired food-carrying strategy (AIFS) by prebinding ginger-derived exosome-like nanoparticles (GELNs) onto probiotics as food depots. AIFS enables probiotics to efficiently and exclusively consume GELNs in situ, even in the presence of competing bacteria. This results in up to 21 times higher uptake efficiency compared to unengineered probiotics, dramatically accelerating probiotic proliferation. Meanwhile, AIFS potentiates probiotics' resistance to multiple GI stressors. In a murine model of colitis, AIFS can improve the abundance of probiotics and inhibit pathogens, maintaining intestinal flora homeostasis. Additionally, it can upregulate the anti-inflammatory IL-10, reduce the proinflammatory IL-1β, and repair damaged intestinal mucus. Thereby, AIFS displays potently elevated prophylactic and therapeutic efficacy for colitis mice. This work provides a method for microbial engineering, with broad implications for microbiotherapy and gut health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.